[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100424617":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":7,"acronym":25,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":7,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":38,"locationsCount":7},{"fullName":5,"class":6},"Kura Oncology, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"DRUG","Tipifarnib",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Kura Medical Information","CONTACT","844-KURAONC (844-587-2662)","medinfo@kuraoncology.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100424617","expanded-access-to-tipifarnib-100424617",false,"NCT04809233","Expanded Access to Tipifarnib","Kuraoncology","Inclusion\u002FExclusion Criteria:\n\nDiagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).\n\nAdult, ages 18+.\n\nHave exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.\n\nIs ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.\n\nMeets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology","ALL","18 Years","EXPANDED_ACCESS","Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).\n\nTo request access, use Responsible Party contact information provided in this record.\n\nExpanded access for tipifarnib is only available in the United States.",[32],"HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)","AVAILABLE","2026-06-24",{"date":36,"type":37},"2026-06-29","ACTUAL",{"name":5,"class":6}]